[Specific features of drug sensitivity of hereditary cancers]

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Traditionally, hereditary cancer gene mutation detection focused on identifying at-risk individuals for monitoring and prevention.
• Emerging research reveals distinct biological features in hereditary cancers, leading to specific drug sensitivities.

Purpose of the Study:

• To highlight the therapeutic potential of targeting specific hereditary cancer types based on their unique genetic and biological characteristics.
• To underscore the shift from risk detection to personalized, targeted treatment strategies in hereditary cancer management.

Main Methods:

• Review of current literature on hereditary cancer genetics and associated drug responses.
• Analysis of specific examples: BRCA1/2-associated cancers, Lynch syndrome, and tuberous sclerosis.

Main Results:

• BRCA1/2-associated cancers exhibit sensitivity to DNA repair inhibitors (e.g., cisplatin, PARP inhibitors) due to double-strand break repair defects.
• Lynch syndrome-related cancers respond well to immune response modulators.
• Tuberous sclerosis-associated tumors show regression with mTOR inhibitors.

Conclusions:

• A growing number of drugs demonstrate specific efficacy against distinct categories of hereditary cancers.
• Targeting the molecular underpinnings of hereditary cancers offers a promising avenue for personalized cancer therapy.